<DOC>
	<DOCNO>NCT01085292</DOCNO>
	<brief_summary>The primary objective trial evaluate safety tolerability multiple intravenous dos NOX-E36 healthy subject patient type 2 diabetes mellitus . A secondary objective trial obtain exploratory estimate pharmacodynamic response level inflammation , metabolism well ongoing diabetes complication ( e.g . impaired cardiovascular , liver renal function ) . Thus , study design provide sufficient safety dose-response data plan Phase IIa proof concept study NOX-E36 patient multiple complication type II diabetes mellitus .</brief_summary>
	<brief_title>NOX-E36 Multiple Ascending Dose Study Healthy Volunteers Patients With Type 2 Diabetes Mellitus</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<criteria>Group A : Healthy male female subject Group BD : Patients type 2 diabetes mellitus accord ADA definition ; GFR &gt; 60 mL/min ; HbA1c ≥ 6.0 ≤9.0 % ; normoalbuminuria , microalbuminuria macroalbuminuria History presence clinically significant disease exception diabetes ( Groups BD ) Concurrent illness may affect blood glucose diabetes Supine blood pressure screening , rest 5 min , &gt; 140 mmHg systolic &gt; 90 mmHg diastolic ( Group A ) &gt; 160 mmHg systolic &gt; 95 mmHg diabetes mellitus patient ( Groups BD ) Clinically significant abnormal ECG screen Any kidney disease cause diabetes hypertension Type 1 diabetes mellitus</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>February 2013</verification_date>
</DOC>